- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06232603
Medication Adherence Intervention in Chronic Recurrent Multifocal Osteomyelitis (CRMO)
Assessing Medication Adherence in Patients With Chronic Recurrent Multifocal Osteomyelitis
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Eric Tham, MD
- Phone Number: 2069872000
- Email: osr@seattlechildrens.org
Study Locations
-
-
Washington
-
Seattle, Washington, United States, 98105
- Recruiting
- Seattle Children's Hospital
-
Contact:
- Yongdong Zhao, MD
- Phone Number: 206-987-2000
- Email: crmoresearch@seattlechildrens.org
-
Contact:
- Emily Schildt, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of CRMO
- Receives clinical care at Seattle Children's Hospital
- On one or more scheduled prescription medications
Exclusion Criteria:
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Education at the first follow up
video and AVS education will be provided at the first follow up visit
|
Video and handout materials will be provided
|
Active Comparator: Education at baseline
video and ambulatory visit summary (AVS) education will be provided at baseline visit
|
Video and handout materials will be provided
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Medication possession ratio (MPR)
Time Frame: 6 to 9 months
|
The MPR is reported as a percentage calculated as: (total prescription days of supply/ (last prescription date - the first prescription date)). For example, if a patient only filled a one-month prescription twice during 6 months, so only had 60 days of medications available during the 6 months, the MPR would be 33%. A MPR of ≥0.8 is generally accepted as good compliance. The MPR data will be calculated for T0 and T1. In order to capture adequate data to calculate the MPR, refill data was acquired for 3 months prior to the beginning of the study (MPR T0) and for 3 months after T1 (MPR T1). |
6 to 9 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Barriers to adherence
Time Frame: 6-9 months
|
A survey will be conducted to determine the barriers predefined and any other barriers
|
6-9 months
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
General Publications
- Semo-Oz R, Wagner-Weiner L, Edens C, Zic C, One K, Saad N, Tesher M. Adherence to medication by adolescents and young adults with childhood-onset systemic lupus erythematosus. Lupus. 2022 Oct;31(12):1508-1515. doi: 10.1177/09612033221115974. Epub 2022 Aug 7.
- Verma T, Rohan J. Examination of Transition Readiness, Medication Adherence, and Resilience in Pediatric Chronic Illness Populations: A Pilot Study. Int J Environ Res Public Health. 2020 Mar 15;17(6):1905. doi: 10.3390/ijerph17061905.
- Saag KG, Bhatia S, Mugavero MJ, Singh JA. Taking an Interdisciplinary Approach to Understanding and Improving Medication Adherence. J Gen Intern Med. 2018 Feb;33(2):136-138. doi: 10.1007/s11606-017-4215-7. No abstract available.
- Len CA, Miotto e Silva VB, Terreri MT. Importance of adherence in the outcome of juvenile idiopathic arthritis. Curr Rheumatol Rep. 2014 Apr;16(4):410. doi: 10.1007/s11926-014-0410-2.
- Favier LA, Taylor J, Loiselle Rich K, Jones KB, Vora SS, Harris JG, Gottlieb BS, Robbins L, Lai JT, Lee T, Kohlheim M, Gill J, Bouslaugh L, Young A, Griffin N, Morgan EM, Modi AC. Barriers to Adherence in Juvenile Idiopathic Arthritis: A Multicenter Collaborative Experience and Preliminary Results. J Rheumatol. 2018 May;45(5):690-696. doi: 10.3899/jrheum.171087. Epub 2018 Feb 1.
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00004426
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Recurrent Multifocal Osteomyelitis
-
Seattle Children's HospitalMansoura University; Boston Children's Hospital, Boston, MA, USA; Hospital for... and other collaboratorsRecruitingChronic Recurrent Multifocal Osteomyelitis | Chronic Nonbacterial OsteomyelitisUnited States
-
Hospices Civils de LyonCompletedChronic Recurrent Multifocal OsteomyelitisFrance
-
Rigshospitalet, DenmarkRegion SjællandActive, not recruitingChronic Recurrent Multifocal OsteomyelitisDenmark
-
Hospices Civils de LyonRecruiting
-
Calvary Hospital, Bronx, NYUnknown
-
Walton Centre NHS Foundation TrustInstituto Grifols, S.A.RecruitingChronic Inflammatory Demyelinating Polyradiculoneuropathy | Multifocal Motor Neuropathy (MMN)United Kingdom
-
TakedaActive, not recruitingChronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Multifocal Motor Neuropathy (MMN)Japan
-
BONESUPPORT ABNot yet recruitingDiabetic Foot Osteomyelitis | Chronic Osteomyelitis | Fracture Related Infection
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingRecurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma | Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaUnited States
-
Institut de Sante Parasport Connecte SynergiesAssistance Publique - Hôpitaux de ParisRecruitingPressure Ulcer | Osteomyelitis | Disability or Chronic Disease Leading to DisablementFrance
Clinical Trials on Education of medication management
-
Medstar Health Research InstituteCompletedType2 Diabetes Mellitus
-
State University of New York at BuffaloNational Center for Advancing Translational Sciences (NCATS)Completed
-
Medstar Health Research InstituteSanofi; Bayer; American Diabetes AssociationCompletedDiabetes Mellitus, Type 2 | Medication Adherence | HYPERGLYCEMIAUnited States
-
Tabula Rasa HealthCareCompletedPharmacogenomics | Medication Therapy ManagementUnited States
-
University of Illinois at ChicagoDuke University; Baylor Research Institute; RTI International; Agency for Healthcare...CompletedElderly Patients | Chronic Illness | Adverse Effects | Medication ErrorsUnited States
-
University of PittsburghWithdrawnMedication Adherence | Adverse Reaction to Drug | Medication NonadherenceUnited States
-
University of North Texas Health Science CenterUniversity of California, San Francisco; University of Minnesota; Walgreens,...Active, not recruitingHypertension | Diabetes Mellitus, Type 2 | HIV/AIDSUnited States
-
Washington University School of MedicineCompleted
-
Ohio State UniversityWithdrawnMedication Therapy Management | Medication Management | Estimated Cost Avoidance | MTM
-
Prof. Iman BashetiCompletedHypertension | Diabetes | Dyslipidemias | Asthma | Cardiac Disease